How Budget Impact Analysis Supports Drug Pricing and Market Access
- Fay
- Jan 2
- 4 min read
Introduction
When a new therapy is preparing to enter the market, policymakers and payers face two critical questions:
Is the drug good value for money? and Can we afford it?
Cost-effectiveness analysis (CEA) addresses the first question, but budget impact analysis (BIA) is designed to answer the second. In modern market access strategies, BIA has become an indispensable complement to CEA, offering a practical view of the financial consequences of adopting a new medicine within real-world budget constraints.
What BIA Measures and Why It Matters
Unlike CEA, which evaluates long-term value using QALYs and ICERs, BIA focuses solely on short- to medium-term affordability. Its goal is straightforward:
How will total healthcare spending change if the new drug is adopted?
To answer this, BIA includes all relevant costs and cost savings that occur from the payer’s perspective, such as:
Drug acquisition and administration costs
Related disease management costs (hospitalizations, monitoring, complications)
Cost offsets when the new treatment prevents expensive events
But crucially, BIA does not claim to measure “value for money.” A drug may be highly cost-effective yet still unaffordable in the short term—especially in systems with fixed annual budgets.
This is why many regulatory and HTA agencies (NICE, CADTH, US payers, and emerging markets) request both CEA and BIA as part of reimbursement dossiers.
How BIA Fits into Pricing and Market Access Decisions
For payers, BIA offers insight into the financial feasibility of adopting a new therapy. For manufacturers, it influences pricing strategy and launch planning in several ways:
Setting a launch price: Companies model BIAs early to understand what price level remains acceptable to payers.
Designing discount or rebate structures: If the BIA shows a large upfront cost spike, manufacturers may offer managed-entry agreements, phased pricing, or rebates.
Supporting negotiations: An appealing BIA can help justify broader formulary coverage or faster uptake.
Anticipating real-world adoption: BIAs estimate how many patients will switch, how fast uptake grows, and where cost pressures may arise.
In short, BIA translates clinical innovation into budgetary reality, shaping both payer decisions and commercial strategies.
Key Components of a BIA
Although BIAs vary across markets, most follow similar steps to generate transparent and reproducible estimates.
1. Define the Target Population
BIA begins by estimating how many patients will be affected. This includes:
Prevalent and incident cases
Untreated patients who may newly seek therapy once the product becomes available
Subgroups defined by disease stage or severity
Accurate population figures are often a key determinant of whether a therapy appears affordable.
2. Establish the Time Horizon
BIA typically uses a shorter time frame than CEA, often 1 to 3 years, aligned with payer budgeting cycles rather than disease progression.
This focus on short-term cash flow is what differentiates BIA from long-term economic models.
3. Determine the Treatment Mix
Analysts evaluate how the new therapy shifts real-world treatment patterns:
Does it replace an older therapy?
Or supplement current care?
What is the expected uptake curve over time?
Understanding displacement is essential because direct cost savings often arise only when a treatment replaces an existing option.
4. Estimate Costs and Cost Offsets
BIA includes only payer-relevant costs, typically excluding patient expenses and development costs. It may cover:
Drug prices
Monitoring or administration
Hospitalizations, complications, adverse events
Disease-related events prevented by the new therapy
Acute conditions may show rapid cost savings; chronic conditions often accumulate savings more slowly.
5. Present Disaggregated Results
A transparent BIA reports:
Costs by year
Costs by category (drug, monitoring, hospitalizations, etc.)
Sensitivity analyses based on population size, uptake, treatment mix, and cost assumptions
This disaggregation helps decision makers identify which components drive affordability concerns.
BIA in Practice: What Real-World Studies Show
A representative example is a U.S. payer-focused BIA evaluating digital interventions for diabetes and hypertension. By integrating implementation costs, medication adjustments, and avoided cardiovascular hospitalizations, the analysis found:
$145 per patient per month savings for type 2 diabetes
$97 per patient per month savings for hypertension
Despite upfront investment, the BIA demonstrated substantial near-term expenditure reductions, precisely the insight payers need to support adoption.
This pattern is common: BIAs often reveal that interventions with modest long-term cost-effectiveness benefits may produce meaningful short-term budget relief.
Why BIA Complements, Not Replaces, CEA
CEA asks whether a therapy is worth the price.
BIA asks whether the payer can afford it right now.
Both perspectives are essential:
A therapy may be cost-effective but unaffordable in the short term.
A therapy may be budget-saving even if its ICER is high.
Policymakers need both analyses to balance value, affordability, and equity.
Together, CEA and BIA allow health systems to move beyond abstract value discussions toward practical, data-based decisions on reimbursement and pricing.
Conclusion
Budget impact analysis has become a cornerstone of modern HTA processes. By connecting clinical benefits to real-world financial consequences, BIA provides the bridge between economic evaluation and practical budget planning. In a world of constrained healthcare resources, understanding both value and affordability is essential—not only for payers, but also for companies seeking successful, sustainable market access for new therapies.
Sources
Assessed and Endorsed by the MedReport Medical Review Board
